Search Follow us

Oxford BioMedica (OXB)

Business description

Oxford BioMedica’s (OXB) LentiVector technology underpins the company’s strategy. OXB generates significant revenue from partners that utilise its technology, notably Novartis, Bioverativ, Orchard Therapeutics and Immune Design. OXB is in partnering discussions about internally developed assets.

Novartis extends manufacturing collaboration

Update | Pharmaceutical & healthcare | 16/10/2014

Novartis has broadened the terms of its CTL019/CART-019 manufacturing collaboration with Oxford BioMedica, with additional incentives for capacity expansion and process optimisation. The new agreement includes $14m upfront, of which $4.3m is an equity stake, with potential to receive a total of $90m over the next three years if the objectives are met. The deal clearly validates both the LentiVector platform and, equally importantly, the production skills and technical expertise being developed.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.£584m
Last close888.400p
High / Low (52 weeks)15.0p / 5.0p
Stock market listingLN
Forecast net debt (£m)9.4
Forecast gearing ratio (%)29
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(10.3)52.9100.8
Relative *(9.5)45.293.0

* % Relative to local index

Company news

Oxford BioMedica

Thu, 15 Feb 2018 10:11:25 GMT

Oxford BioMedica

Fri, 20 Dec 2013 02:29:24 GMT

Oxford BioMedica

Fri, 08 Sep 2017 15:08:45 GMT

Oxford BioMedica

Fri, 24 Mar 2017 18:00:00 GMT

Oxford BioMedica

Fri, 16 Mar 2018 11:35:39 GMT